A rterial stiffness represents the loss of compliance in arterial walls, resulting in a series of detrimental hemodynamic sequelae, including elevated systolic blood pressure, widened pulse pressure, increased left ventricular hypertrophy, and reduced diastolic coronary perfusion.
A rterial stiffness represents the loss of compliance in arterial walls, resulting in a series of detrimental hemodynamic sequelae, including elevated systolic blood pressure, widened pulse pressure, increased left ventricular hypertrophy, and reduced diastolic coronary perfusion. 1, 2 A growing body of evidence including a recent scientific statement from the American Heart Association 2 documents that excessive arterial stiffness precedes hypertension and contributes to longstanding hypertension-related organ damage by stiffening large arteries, including vessels in the heart, brain, and kidneys. 2, 3 Two recent meta-analyses of longitudinal observational data consistently reported the predictive value of an elevated baseline arterial stiffness for future cardiovascular events and all-cause mortality independent of standard cardiovascular risk factors, including blood pressure. 4, 5 Pulse wave velocity (PWV) has widely been recognized as a reliable and accurate method to quantify arterial stiffness. 2, 6 The current measurement technique for PWV is noninvasive, simple, and inexpensive. 2, 7 To date, however, limited data have documented the clinical significance of reversing PWV. Besides, few proven therapeutic modalities are available to prevent or reverse the progression of arterial stiffness.
Recent work has identified that vascular calcification is an active and regulated process of calcium mineral deposition in arterial walls. [8] [9] [10] Calcification within the aorta has been established as a risk factor for cardiovascular morbidity and mortality. 11, 12 Also multiple conventional risk factors, including age, blood pressure, and smoking, are associated with aortic calcification. 13 We 14 and others [15] [16] [17] [18] [19] have reported a significant positive association between aortic calcification and arterial stiffness in cross-sectional data of healthy population, 14, 16, 19 as well as in patients with isolated systolic hypertension, 17 peripheral arterial disease, 20 and chronic kidney disease. 21 However, the cross-sectional nature of these studies limits conclusions on temporality.
The aim of the present study was to prospectively evaluate the association of longitudinal increase in aortic calcification with progression of arterial stiffness in a population-based sample of apparently healthy middle-aged men from the ERA JUMP study (Electron-Beam Computed Tomography and Risk Factor Assessment in Japanese and US Men in the PostWorld War II Birth Cohort).
Methods Participants
The ERA JUMP is a longitudinal, population-based cohort study of men aged 40 to 49 years who were free from cardiovascular or other severe diseases at baseline. The detail of the study design was described previously. 22, 23 Participants were recruited from 3 communities (n=1033): white Americans and black Americans from the Allegheny County, PA (310 white and 107 black); Japanese Americans from Honolulu, Hawaii (n=303); and Japanese from Kusatsu, Shiga, Japan (n=313). Of 1033 participants, 398 (38.5%) were excluded either for loss to follow-up (n=246) or for missing brachial-ankle PWV (baPWV) and aortic calcification data (n=152). The eligible sample size was 635 participants for the present analyses. The study protocol was approved by the Institutional Review Boards of the University of Pittsburgh, Pittsburgh, PA, Kuakini Medical Center, Honolulu, Hawaii, and Shiga University of Medical Science, Otsu, Japan.
Participants made 2 visits, a baseline visit taking place between 2002 and 2006 and a follow-up visit 4 to 7 years later. Physical examination, laboratory assessment, and lifestyle questionnaire were performed at each visit. Information about age, race, smoking status (categorized with ≥20, 0 to <20, and 0 pack-years), and use of antihypertensive, lipid-lowering and hypoglycemic medications were obtained by questionnaires. Body mass index was calculated as the weight in kilograms divided by the square of the height in meters (kg/m 2 ). Blood pressure and heart rate were examined after participants had emptied their bladders and had sat quietly for 5 minutes. Blood pressure was measured twice on the right arm using an appropriately sized cuff and automated sphygmomanometer (BP-8800; Colin Medical Technology, Komaki, Japan), and an average of the 2 measures was recorded. Mean arterial pressure was determined as 1/3 (systolic blood pressure−diastolic blood pressure)+diastolic blood pressure. Hypertension was defined as systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥ 90 mm Hg or use of antihypertensive medications.
Blood samples were collected in the morning after a 12-hour fast. All blood samples were stored at −80°C and shipped on dry ice to the Heinz Nutrition Laboratory, University of Pittsburgh (lipids and glucose) and University of Vermont (C-reactive protein). Serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were determined using standardized protocols from the Center for Disease Control and Prevention. 24 Serum glucose was determined using a hexokinase glucose-6-phosphate-dehydrogenase enzymatic assay. Diabetes mellitus was defined as a fasting blood glucose level ≥7.0 mmol/L or use of hypoglycemic medications. C-reactive protein was tested using a colorimetric competitive ELISA. Data collection procedures were standardized across all study sites.
Brachial-Ankle PWV
The Ultrasound Research Laboratory at the University of Pittsburgh provided training for the standardized PWV assessment. baPWV was measured at baseline and repeated at follow-up. A noninvasive automated waveform analyzer (VP2000; Omron Co., Komaki, Japan) was used with appropriate-sized cuffs. After 10 minutes of rest in the supine position, occlusion and monitoring cuffs were placed around both the arms and ankles of the participant. ECG electrodes were placed on both wrists and a phonocardiogram on the left edge of the sternum. The path lengths for baPWV were calculated using a heightbased formula. 25 baPWV was determined as the distance between arterial sites divided by the time between the feet of the respective waveforms. Measurements were performed twice, and the averaged value was recorded. Intraclass correlations for the baPWV measurements were 0.97 within technician and 0.91 between technicians.
14 BaPWV was measured on both the left and right sides, and the average value was used in this study.
Aortic Calcification
Aortic calcification was measured both at baseline and follow-up visits. At baseline, all 3 study sites (Pittsburgh and Honolulu in the United States and Shiga in Japan) and follow-up in Pittsburgh site, electron beam tomographic scans were performed using a GE-Imatron C-150 scanner (GE Medical Systems, South San Francisco, CA).
14 A 64-slice multidetector tomographic scans (VCT-64; GE Healthcare, Waukesha, WI) was used at follow-up in the Honolulu site, and a 16-slice multidetector tomographic scans (Toshiba Medical System Corporation, Tochigi, Japan) 26 was used at follow-up in the Shiga site. All scan data were saved to optical disc and shipped to the Cardiovascular Institute, University of Pittsburgh Medical Center for evaluation. Images were read by 1 trained reader, and the reader was blinded to participants' characteristics and study sites. For aortic calcification evaluation, 6-mm-thick transverse contiguous images were obtained from the level of the aortic arch to the iliac bifurcation using a 300-ms exposure time. Calcium was considered present in the aorta when at least 3 contiguous pixels of 130 Hounsfield Units was present on a 30-cm matrix. Aortic calcium score was quantified by the method of Agatston et al. 27 The intraclass correlation within reader was 0.98.
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Statistical Analyses
We examined descriptive characteristics of the study population, including demographics, cardiovascular risk factors, aortic calcification, and baPWV. Categorical variables were presented as number (%) and continuous variables as mean (SD) or median (interquartile range) according to the distribution of variables. The progression of baPWV was defined as an average annual change determined by the absolute difference between-visit change in baPWV divided by the follow-up time in years. The annual change in aortic calcium score was calculated similarly. Because both baseline aortic calcium score and its annual change were highly skewed to the right with a comparably large proportion of zero values (baseline aortic calcium score and its annual change had 46.8% and 22.8% of zero values, respectively), we categorized them for the regression analyses. The baseline aortic calcium score was categorized into 4 groups: 0, 1 to 100, 101 to 400, and >400; and its annual change was also classified into 4 groups: ≤0, 1 to 10, 11 to 100, and >100.
We used general linear regression to examine the association between aortic calcification and arterial stiffness. We initially examined the baseline cross-sectional association between aortic calcification and baPWV. Three multivariable models were performed to progressively adjust for potential confounders according to a systematic review of arterial stiffness, 29 indicating a strong association of arterial stiffness with age, blood pressure, and heart rate, a moderate association with diabetes mellitus and a weak association with HDL-C, LDL-C, and triglycerides. We initially adjusted for age, race, mean arterial pressure, and heart rate (model I); model II further adjusted for body mass index, smoking status, use of antihypertensive medication, and diabetes mellitus; and model III additionally adjusted for HDL-C, LDL-C, triglycerides, use of lipid-lowering medications, and C-reactive protein. Second, the association of the annual change in aortic calcification with baPWV progression was examined controlling for baseline aortic calcification and baPWV. For multivariable-adjusted regression analyses of baPWV progression, besides using the 3 models (models I-III) described above, model IV (fully adjusted model) was performed to additionally adjust for the annual change in body mass index, mean arterial pressure, HDL-C, LDL-C, and triglycerides. Finally, multivariable-adjusted regression (models I -IV) was performed in subgroups without and with prevalent aortic calcification at baseline. For those who were free from aortic calcification at baseline, we tested an association of the incidence of calcification over the follow-up period with arterial stiffness progression. For those who had prevalent aortic calcification at baseline, we investigated the association of an increase in calcification over the follow-up period with arterial stiffness progression. Log transformation was applied to highly skewed variables, ie, HDL-C, triglycerides and their annual changes, and C-reactive protein. A two-sided P value <0.05 was considered statistically significant. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC).
Results
The study cohort, followed up for 5.6 (0.9) mean (SD) years, was relatively young (mean [SD] : age, 45.2 [2.9] years; range, 40-49 years) and healthy (23.0% with hypertension, 7.0% with diabetes mellitus, and 10.9% using lipid-lowering medications; Table 1 ). The baseline baPWV was approximately normally distributed, with a mean (SD) of 1345.8 (174.7) cm/s (range, 919.5-2217.5 cm/s). The average annual change in baPWV ranged from −78.8 to 86.3 cm/s, negative values represent a reduction whereas positive values represent an increase over the follow-up time relative to the baseline levels. BaPWV was normally distributed with a mean (SD) of 8.6 (22.9) cm/s per year ( Table 1) .
The baseline aortic calcium score ranged from 0 to 4139 with a median (interquartile range) of 3 (0-41). There were 297 (46.8%) participants without and 338 (53.2%) with prevalent aortic calcification at baseline. The annual change in aortic calcium score ranged from −358.7 to 890.4 with a median (interquartile range) of 6.9 (0-41.6). Of all participants, 46 (7.2%) had a reduction in aortic calcification over the followup period relative to baseline levels; 145 (22.8%) exhibited no change; and 444 (69.2%) showed an increase.
In regression analyses for baseline measures (Table 2) , aortic calcification had a positive and significant association with baPWV after adjusting for age, race, mean arterial pressure, and heart rate (model I); after further adjusting for body mass index, smoking status, use of antihypertensive medications, and diabetes mellitus (model II); and after additionally adjusting for HDL-C, LDL-C, triglycerides, use of lipid-lowering medications, and C-reactive protein (model III). In model III, the adjusted mean (SD) of baseline baPWV increased across aortic calcification categories (P for trend=0.023).
We further examined the association of longitudinal changes in aortic calcification with arterial stiffness progression over the follow-up period with controlling for baseline baPWV, aortic calcification, and other risk factors. Annual change in aortic calcification was positively and significantly associated with baPWV progression in multivariable-adjusted regression analyses in models I to IV (Table 3 ). In the fully adjusted regression model (model IV), at each category of annual change in aortic calcium score ≤0, 1 to 10, 11 to 100, and >100, the adjusted mean (SD) for the annual change in baPWV was 3.8 (2.2), 7.2 (2.2), 12.2 (1.8), and 15.6 (2.6) cm/s, respectively (P for trend=0.001). baPWV indicates brachial-ankle pulse wave velocity; BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoproteincholesterol; and MAP, mean arterial pressure.
*Categorical variables were presented as number (%) and continuous variables as mean (SD) or median (25th percentile, 75th percentile) according to the distribution of variables.
In the subgroup of participants without aortic calcification at baseline (n=297), the incidence of aortic calcification over the follow-up period was an independent determinant of greater arterial stiffness progression (models I-IV; Table 4 ). In the fully adjusted regression model (model IV), for participants without or with incident aortic calcification, the adjusted mean (SD) of annual change in baPWV was 2.3 (2.3) and 8.7 (1.9) cm/s, respectively (P for trend=0.009). In the subgroup of participants with prevalent aortic calcification at baseline (n=388), an increase in aortic calcification over the followup period was also significantly associated with greater arterial stiffness progression (models I-IV; Table 5 ). In the fully adjusted regression model (model IV), for participants without or with an increase in aortic calcification, the adjusted mean (SD) of the annual change in baPWV was 2.7 (3.3) and 11.0 (1.5) cm/s, respectively (P for trend=0.018). We found no significant interaction between race and baseline aortic calcification or between race and annual change in aortic calcification (data not shown).
Discussion
We observed that longitudinally increases in aortic calcification were an independent prognostic factor for greater progression of arterial stiffness after adjusting for standard cardiovascular risk factors in a population-based sample of healthy middle-aged men. The results remained consistent after additional subgroup analyses. In the subgroup initially free of aortic calcification, the development of aortic calcification over the follow-up period was significantly associated with greater arterial stiffness progression. In the subgroup with prevalent aortic calcification at baseline, arterial stiffness had significantly greater progression in participants with increased aortic calcification than in those with reduced aortic calcification, over the follow-up period.
Our findings suggest a temporal relationship between aortic calcification and arterial stiffness. In a study 21 of 134 patients with end-stage chronic kidney disease, a simple positive correlation between absolute changes in vascular calcification and arterial stiffness was observed. However, this study was limited to the superficial femoral artery and had only 2 years of follow-up. Whereas we investigated the relation between aortic calcification and arterial stiffness in a longitudinal study with up to 7 years follow-up, utilizing a multivariable-adjusted model in healthy population-based samples.
A plethora of evidence documents its prognostic value for future cardiovascular events independent of established risk factors. 4, 5, 30 Such information underscores the importance of better understanding the mechanism underling arterial stiffening, which cannot be entirely explained by established risk factors. 10 Our results potentially suggested a causal link between aortic calcification and arterial stiffness. This may at least partially explain the mechanism that whereby arterial stiffness leads to vascular disease burden beyond established cardiovascular risk factors.
Aging is associated with structural and mechanical changes in arteries, including reduced elasticity and increased stiffness. 31 The process of arterial stiffness involves migration Model I: adjusted for age, race, mean arterial pressure, and heart rate; model II: further adjusted for body mass index, smoking, hypertension medication, and diabetes mellitus; and model III: further adjusted for high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, lipid-lowering medication, and C-reactive protein. baPWV indicates brachialankle pulse wave velocity. Model I: adjusted for age, race, MAP, and heart rate; model II: further adjusted for BMI, smoking, hypertension medication, and diabetes mellitus; model III: further adjusted for HDL-C, LDL-C, triglycerides, lipid-lowering medication, and C-reactive protein; and model IV: further adjusted for annual changes in BMI, MAP, HDL-C, LDL-C, and triglycerides. baPWV indicates brachial-ankle pulse wave velocity; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and MAP, mean arterial pressure.
of vascular smooth muscle cell into media, an increase in the ratio of collagen to elastin, and calcification. 31, 32 Vascular calcification is a process of mineralization of the internal elastic lamina and elastic fibers in the arterial wall resulting in stiffening. 8, 31, 33 Vascular calcification is a hallmark of vascular aging. 32 Animal models have shown that calcification in both the medial 34, 35 and intimal 32 layers of the aorta contributes to an increase in arterial wall stiffening.
Our findings add evidence to the hypothetical contribution of aortic calcification to arterial stiffness and support the hypothesis that anticalcification therapies may be a potential therapeutic modality for preventing or ameliorating arterial stiffness. A better understanding of the cellular and molecular disease may lead to more efficient therapeutic strategies for targeting vascular calcification. For example, animal models demonstrated that the endothelin receptor antagonist can reduce medial arterial calcification. 36, 37 Besides, the biguanide metformin may inhibit calcification by increasing nitrogen monoxide production. 38 Animal models have also shown an association between several molecules, including ghrelin 39 and intermedin with vascular calcification. 40 Yet data from human studies are lacking. Future investigations in animals and humans are needed to explore the effectiveness and safety of novel interventions for reducing arterial stiffening by inhibiting calcification.
In the present study, the baseline prevalence of aortic calcification was 53.2%. The cohort of the Framingham Heart Study Third Generation cohort reported a prevalence of 39% for aortic calcification. Their cohort had a similar age (a mean of 44.9 years), but they enrolled both sexes (45% women), which may explain the lower prevalence when compared with our results. There were only 10 (1.6%) participants who had baseline baPWV >1800 cm/s-a cutoff value used in the assessment of cardiovascular disease risk according to a position paper of the European Society of Cardiology Working Group, 6 thus emphasizing the healthy status of our cohort. In addition, we observed a positive and significant crosssectional association between aortic calcification and arterial stiffness at baseline, which is in agreement with previous results, including ours. [14] [15] [16] [17] [18] [19] 41 Clinical meaningful cutoff values of aortic calcium scores in the healthy population are unknown although some investigators use cut points of 100, 300, or 400.
14, 42 We used cutoff points of 0, 100, and 400 for baseline aortic calcium and 0, 10, and 100 for the annual change. The data were also analyzed with quartiles for both baseline aortic calcium score and its annual change, and the results remained consistent (data not shown).
The strengths of our study were its longitudinal design and well-characterized population-based samples free of overt cardiovascular disease. We also evaluated calcification of the entire aorta instead of distinct segments of thorax and abdomen. Advantages of our cohort also include a comparably large sample size, inclusion of diverse ethnicities, and a relatively long period of following up. Several limitations of the study warrant discussion. The present imagining technology does not allow a distinction between intimal calcification and medial calcification; thus, our study cannot evaluate the individual effect of these 2 forms of calcification on arterial stiffness. baPWV, as a combined measure of stiffness for central and peripheral arteries, was used in the present study. Carotidfemoral PWV remains the golden standard of measuring the stiffness of central arteries. On the contrary, baPWV has been worried as a measure for central arterial stiffness because of its anatomic property including long muscular artery. However, baPWV exhibits a high correlation with carotid-femoral PWV (correlation coefficient r=0.73) 43 and a similarly strong ability to predict future cardiovascular events. [44] [45] [46] [47] [48] [49] [50] [51] The ERA JUMP cohort only included men aged from 40 to 49 years old at baseline, and thus the results may not be generalizable to women or other age groups.
Perspectives
This is the first prospective cohort study to investigate the relationship between aortic calcification and arterial stiffness. Increased aortic calcification was an independent determinant Model I: adjusted for age, race, MAP, and heart rate; model II: further adjusted for BMI, smoking, hypertension medication, and diabetes mellitus; model III: further adjusted for HDL-C, LDL-C, triglycerides, lipid-lowering medication, and C-reactive protein; model IV: further adjusted for annual changes in BMI, MAP, HDL-C, LDL-C, and triglycerides. baPWV indicates brachial-ankle pulse wave velocity; BMI, body mass index; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and MAP, mean arterial pressure. Model I: adjusted for age, race, MAP, and heart rate; model II: further adjusted for BMI, smoking, hypertension medications, and diabetes mellitus; model III: further adjusted for HDL-C, LDL-C, triglycerides, lipid-lowering medication, and C-reactive protein; model IV: further adjusted for annual changes in BMI, MAP, HDL-C, LDL-C, and triglycerides. baPWV indicates brachial-ankle pulse wave velocity; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and MAP, mean arterial pressure.
of greater progression of arterial stiffness in healthy middleaged men after adjusting for standard cardiovascular risk factors. Arterial stiffness is related to the pathogenesis of hypertension and is an independent predictor of cardiovascular morbidity and mortality. Our findings imply that aortic calcification may contribute to the stiffening of arteries. Future investigations are needed to identify the value of aortic calcification as a potential therapeutic target to limit or reverse the stiffening process of arteries and thus reduce the disease burden that is attributable to excessive arterial stiffness.
